25 May 2013
Keywords: targacept, tc-1734, shows, promise, memory, study, usa-based
Article | 29 May 2006
USA-based biopharmaceutical group Targacept says that it has seen positive results from Phase II trials of TC-1734 (AZD3480) in the
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 May 2006
24 May 2013
© 2013 thepharmaletter.com